BrainSpace, a medtech focused on neurological injuries and illnesses, received 501 (k) clearance from the FDA for its brain ...

Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Naox Technologies has become the first medtech company to receive FDA clearance for its in-ear EEG device that can negate the ...

With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026.

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...